Differential response of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose

Diabetes Care. 1995 Feb;18(2):272-3. doi: 10.2337/diacare.18.2.272.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Controlled Clinical Trial
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acarbose
  • Apolipoproteins B / blood*
  • Apolipoproteins B / drug effects
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use*
  • Lipoprotein(a) / blood*
  • Lipoprotein(a) / drug effects
  • Male
  • Middle Aged
  • Time Factors
  • Trisaccharides / therapeutic use*

Substances

  • Apolipoproteins B
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Lipoprotein(a)
  • Trisaccharides
  • Acarbose